ArticleBlood transfusion = Trasfusione del sangue2021
SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
Article in Blood transfusion = Trasfusione del sangue, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 7 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Pooled it
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).Addiction (Abingdon, England) · 2021Pooled it
- The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review.PloS one · 2021Pooled it
- A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.European journal of epidemiology · 2020Pooled it
- IFNAR2 p.F8S Variant Associates with Severe COVID-19 and Adaptive Immune Cell Activation Modulation.International journal of molecular sciences · 2026Article
- Article
- An Epidemiological Assessment of SARS-CoV-2 in the Sewage System of a Higher Education Institution.Annals of global health · 2024Article
- Analysis of the prevalence of anti-SARS-CoV-2 antibodies in groups of medical and non-medical professions.International journal of occupational medicine and environmental health · 2023Article
- Association between ABO blood groups and SARS-CoV-2 infection in blood donors of Puglia region.Annals of hematology · 2023Observational
- COVID-19 Vaccination and Serological Profile of a Brazilian University Population.Life (Basel, Switzerland) · 2023Article
- Seroprevalence of COVID-19 in Oran: Cross-Sectional Study.Microbiology spectrum · 2023Article
- Serosurveillance of SARS-CoV-2 in Welsh Blood Donors: Establishment of the surveillance system and results up to November 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.PloS one · 2023Article
- Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.PLOS global public health · 2023Article
- Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy.Environmental research · 2022Article
- A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?Human vaccines & immunotherapeutics · 2022Article
- Is SARS-CoV-2 screening still necessary before hematopoietic stem cell donation? Observations from a single center and review of the literature.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Milan metropolitan area in Northern Italy was among the most severely hit by the SARS-CoV-2 outbreak. The aim of this study was to examine the seroprevalence trends of SARS-CoV-2 in healthy asymptomatic adults, and the risk factors and laboratory correlates of positive tests. MATERIALS AND
methodsWe conducted a cross-sectional study in a random sample of blood donors, who were asymptomatic at the time of evaluation, at the beginning of the first phase (February 24
resultsThe test had a 100/98.3 sensitivity/specificity (n=32/120 positive/negative controls, respectively), and the IgG test was validated in a subset by an independent ELISA against the Spike protein (n=34, p<0.001). At the start of the outbreak, the overall adjusted seroprevalence of SARS-CoV-2 was 2.7% (95% CI: 0.3-6%; p<0.0001 vs 120 historical controls). During the study period, characterised by a gradual implementation of social distancing measures, there was a progressive increase in the adjusted seroprevalence to 5.2% (95% CI: 2.4-9.0; 4.5%, 95% CI: 0.9-9.2% according to a Bayesian estimate) due to a rise in IgG reactivity to 5% (95% CI: 2.8-8.2; p=0.004 for trend), but there was no increase in IgM DISCUSSION: SARS-CoV-2 infection was already circulating in Milan at the start of the outbreak. The pattern of IgM/IgG reactivity was influenced by age: IgM was more frequently detected in participants aged >45 years. By the end of April, 2.4-9.0% of healthy adults had evidence of seroconversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.